John Huxley, John Shirley, Rosemary Righter, Richard Buckle, Victoria Glendinning, Jean Rafferty, Ann Gould, John Vincent, Chris Tighe, Christopher Reid, Professor P. D. Wall Director, Jimmy Savile, Peter Calvocoressi, Berry Ritchie, Graham Rose, John Diamond, Elisabeth Dunn, Richard Lamb, Wiill Ellsworth Jones, Christopher Peace, Robin Morgan, John Whale, Nick Pitt, Claire Chovil Head of School Broadcasting (Radio), John Huxley Industrial Editor, Cal McCrystal, Jason Tomas, Henry Porter, Mark Hosenball, Jancis Robinson, Diego Garcia, Dora Chof, Julie Covington, Robert Hewison, Joan Didion, Mick Brown, Deryk Brown, Keith Botsford, Robin Wright, R K Piggott, Mitchell Platts, David Dougill, Joe Irving, Eric Korn, Robert Moore, Derek Jewell, Alexandra Watson, Nicky Brierley, Susan Crosland, David Cairns, Marina Warner, Adrianne Blue, Norman Harris, Donald Macintyre Labour Editor, Donald Macintyre, Al Weil, Giles Merritt, Geoff Whitten, Peter Ackroyd, Lionel Barber, Michael Jones, Geoffrey Cannon, Kevin Edwards, Chris Coldrey, Kevin Suttie Student, George Perry, Robin Marlar, Tony Willard, Richard Downs, John Sheppard, M Senior, David Irving, Brian Moynahan, G. H. Dickson, Roger Eglin, James Tucker, Peter Shearlock, Paul Driver, Muriel Bowen Local government Correspondent, Richard Brooks, David Hughes, Glenys Roberts, Claire Tomalin, Judith Jackson, Brian Clarke reports, Brian Morris, Nick Gilbert, Celia Haddon, David Lipsey Economics Editor, Eric Marsden, Jsabel Hilton, Jonathan Raban, John Baliantine, Hugo Young Political Editor, Peter Sherlock, Bryan Silcock, Simon Freeman, James Wilson, Elaine Potter, Simon Frith, David May, Philip Venning Builder, Tony Levene, Alan Brien, Norman Lebrecht, Russell Davies, Martin Kettle, David Lipsey, A F Jervis, Brough Scott, Deyan Sudjic, Caroline McGhie, Clive Everton, David Wagstaffe Housing Manager, Kim Fletcher, Dudley Doust, Clare Dyer, Peter Wilby, Gitta Sereny, G R Rodgers Managing Director, Susan Raven, Peter Shearlock City Editor, Mihir Bose, Peter Clarke, Andrew Stephen, Suzanne Lowry, Paul Barker, Brian Glanville, Michael Booth, James Fenton, Charles Gans, Michael Jones Political Correspondent, A M Fraser Chairman, Marina Vaizey, Amir Taheri, Peter Wilby Education Correspondent, Philip Jacobson, Robert Kilroy-Silk Member of Parliament, Monty Schaffer, Harry Coen, Patience Wheatcroft, Roger Ratcliffe, Joan Smith, Leslie Geddes-Brown, Boris Schapiro, Anthony Terry,
... Points Sympathetic move 'Evita' earnings Carry on counting Depo-Provera: makers reply Ford The day of the ephemera25 ...
1983 - Gale Group | Sunday Times HA GDA
Diana Liew, Charles S.A. Ng, Y.M. Yong, S.S. Ratnam,
Long-term effects of injection Depo-Provera (depo-medroxyprogesterone acetate) on carbohydrate and lipid metabolism were studied in 157 women who were treated continuously for a mean duration of 43. ... than 0.001). In view of these findings, Depo-Provera may have an advantage over oral pills on ...
Tópico(s): Diabetes, Cardiovascular Risks, and Lipoproteins
1985 - Elsevier BV | Contraception
By Peter Wilson-Smith and Frances Williams, From Our Correspondent, By Frances Williams, Economics Correspondent, By Paul Routledge, Labour Editor, By Michael Horsnell, From Ivor Davis, By Julian Haviland Political Editor, From Andrew Thompson Buenos Aires, By Huon Mallalieu, By Philip Webster political Reporter, Anthony Bevins, Political Correspondent, concludes his examination of the parliamentary candidate selection procedures with the Labour Party., From David Felton Labour Correspondent Dundee, By Anthony Bevins, Political Correspondent, By Kenneth Gosling, From Pearce Wright Science Editor, By Harry Golombek Chess Correspondent, By Clifford Longley, Religous Affairs Correspondent, From Our Correspondent, Winchester, By Christopher Warman, Arts Correspondent, By David Walker, From Ian Murray, Brussels, From Roger Boyes, Warsaw, From Grania Forbes, PA Court Correspondent, Brisbane, From George Clark Strasbourg, From Richard Owen, Moscow, From Geoffrey Matthews, Bogota, From Mohsin Ali, From Nicholas Ashford, Washington, From Rasit Gurdilek, From Christopher Walker, From Our Own Correspondent, From Michael Hornsby, Anthony Masters, John Percival, Paul Griffiths, Clare Colvin, Dennis Hackett, Richard Williams, Jenny Bryan, From J. R.Heron, Consultant Neurologist, North Staffordshire Hospital Centre, Hartshill, Stoke-on-Trent., By Christopher Thomas, PHS, Bernard Levin:, Michael Hornsby, David Hewson, Brian Crozier, MARTIN BARBER, BRIAN WALKER, JOHN A. CUMBER, JOYCE PEARCE, D. BRYCE-SMITH, , GEOFFREY LEE WILLIAMS, , GLANVILLE WILLIAMS, , EDWARD TOWNE, , BARBARA K. HOWELLS, , D. F. PERRYMAN., HALLAM MURRAY, , BRUCE ARCHER, , S. C. J. PALMER, , MICHAEL FIORINI., By Geraldine Norman, Sale Room Correspondent, By Philip Howard, City Editor Anthony Hilton, From Maxwell Newton, From Bailey Morris, By Jeremy Warner, By Peter Wilson-Smith, Banking Correspondent, By Andrew Cornelius, By Our Financial Staff, By Edward Townsend, Industrial Correspondent, By Jonathan Clare, edited by Sally White, Frances Williams, Edward Townsend, by Michael Clark, By Stuart Jones, Football Correspondent, By Richard Eaton, By Gerald Richmond, By David Hands, Rugby Correspondent, By George Ace, Alan Gibson, By John Woodcock, Cricket Correspondent, By Michael Phillips, Racing Correspondent, By Michael Seely, By Dick Hinder, By Ian Reid, By Lewine Mair, From A Special Correspondent, Jenny MacArthur, From Joyce Whitehead, Kuala Lumpur, Baron Phillips, Edited by Peter Dear, From Alan Hamilton, Port Stanley, Frank Johnson in the Commons,
... Transport of delight across the Irish Sea Connemara, Depo-Provera: a drug on trial, Return of a Falklands ...
1983 - Gale Group | TDA
Karen H. Lu, David S. Loose, Melinda S. Yates, Graciela M. Nogueras‐González, Mark F. Munsell, Lee-may Chen, Henry T. Lynch, Terri L. Cornelison, Stephanie Boyd-Rogers, Mary Rubin, Molly S. Daniels, Peggy Conrad, Andrea Milbourne, David M. Gershenson, Russell R. Broaddus,
... were randomized to receive the progestin compounds Depo-Provera (depo-MPA) or OCP for three months. An endometrial ...
Tópico(s): RNA Research and Splicing
2013 - American Association for Cancer Research | Cancer Prevention Research
By Stewart Tendler, By Julian Haviland, Politicai Editor, From Zoriana Pysariwsky, By Anthony Bevins Political Correspondent, From Christopher Thomas, From Michael Hornsby, From Roger Boyes, By Donald Macintyre, Labour Correspondent, By Philip Webster, Political Reporter, By A Staff Reporter, By Paul Routledge, By Our Transport Correspondent, From Frances Gibb, By Anthony Bevins, Political Correspondent, By Our Labour Editor, By Geraldine Norman Sale Room Correspondent, By John Young, By Jeanette Mitchell, By Hugh Clayton, By David Fellon, By Pearce Wright, By Hugh Clayton, Environment Correspondent, By Lucy Hodges, By David Nicholson-Lord, By a Staff Reporter, By Richard Evans, By Clifford Longley, Religious Affairs Correspondent, By Michael Baily, Transport Correspondent, By Pat Healy Social Services Correspondent, By Henry Stanhope, Defence Correspondent, By Our Political Staff, From George Clark, By Nicholas Timmins, From John Witherow on board HMS Invincible, From Nicholas Ashford, By Edward Mortimer, By Our Defence Correspondent, From Alan McGregor, From David Blow, From Robert Fisk, From Patricia Clough, From Micheal Hamlyn, From Charles Harrison, From Stephen Taylor, From Jacqueline Reditt, From Harry Debelius, From Ian Murray, From Charles Hargrove, From Mario Modiano, From Paul Ellman, From Michael Hamlyn, Anthony Quinton, Ronald Lewin, H. R. F. Keating, Philip Ziegler, Miranda Seymour, Richard Holmes, Alan Hamilton, PHS, Ronald Butt, CAROLINE PINDER, JANE PRIOR, JOHN STOKES, MICHAEL COCKERELL, SANDY GALL, STEPHEN HUGH-JONES, ANGUS MAUDE, S. L. BLACKMORE, ELIZABETH BEAMISH, E. PETER HEATH, J. COLIN NICHOLS, JAMES JONES, LEONARD COX, P. W. DUNCANSON, MICHAEL LEVI, BARBARA MADDRELL, T. J. PHILLIPS, Peter Ackroyd, Irving Wardle, David Robinson, Paul Griffiths, Msx Harrison, By Derek Harris, By Philip Robinson, By Michael Parrott, John Earle, From Peter Norman, From Nicholas Hirst, By Peter Wilson-Smith, Derek Harris, C. Gordon Tether, By Sydney Friskin, By Norman Fox, By Stuart Jones Football Correspondent, By Richard Eaton, By Leslie Duxbury, By Alan Gibson, By Richard Streeton, By John Woodcock, Cricket Correspondent, From Rex Bellamy, Tennis Correspondent, By Alan Ross, By Lewine mair, By Pamela MacgregorMorris, By Michael Seely, By Our Racing Correspondent, By Our Newmarket Correspondent, By Michael phillips, Racing Correspondent, By John Hennessy, By John Wilcockson, From Special Correspondent, Philip Schofield, Michel Syrett, Edited by Peter Davalle, From Richard Wigg, From Tim Jones, PH, By Clifford Longley, Richard Dowden,
... pay rise, Punishment 'Parole system given greater flexibility, Depo-Provera risks outweigh the benefits, After the announcement that, ...
1982 - Gale Group | TDA
Produção Nacional
Revisado por pares
Douglas Taylor, Vera Halpern, Vivian Brache, Luís Bahamondes, Jeffrey T. Jensen, Laneta J. Dorflinger,
... of ovulation for investigational subcutaneous regimens of Depo-Provera CI (Depo-Provera) and Depo-subQ Provera 104 (Depo-subQ).We performed a secondary analysis of 2 ... assessed the pharmacokinetics and pharmacodynamics of MPA when Depo-Provera is administered subcutaneously rather than by the labeled ... 45 mg to 300 mg subcutaneous injection of Depo-Provera, a single 104 mg subcutaneous injection of Depo- ... extended to four months or if 150 mg Depo-Provera were injected subcutaneously every 6 months.Extending the ...
Tópico(s): Ectopic Pregnancy Diagnosis and Management
2022 - Elsevier BV | Contraception X
From Our Correspondent, Liverpool, From Nicholas Ashford, Washington, From Diana Geddes Paris, By Anthony Bevins, Political Correspondent, From Michael Hornsby Johannesburg, By Nicholas Timmins, By Rupert Morris, By Pat Healy, Social Services Correspondent, From Arthur Osman, Birmingham, By the Staff of Nature, By Kenneth Gosling, By Bill Johnstone, Electronics Correspondent, By Bill Johnstone Electronics Correspondent, From Our Correspondent, From Ronald Faux, By Sydney Friskin, From Richard Ford, Belfast, By David Walker, Local Government Correspondent, By Frances Gibb, By Hugh Clayton, Environment Correspondent, From Christopher Walker, Jerusalem, From Roger Boyes, Warsaw, By Richard Dowden, From Martha Honey Puntarénas, Costa Rica, From Michael Binyon, Bonn, From Stephen Taylor, From Bailey Morris, From Mario Modiano, From Ian Murray, From Christopher Thomas, New York, From W. P. Reeves, From Diana Geddes, Paris, From Harry Debelius, From Richard Wigg, Madrid, From Our Own Correspondent, From Susan MacDonald, From John Earle, From Richard Hanson, From Tony Duboudin, PHS, Richard Body, Peter Melchett, Michael Binyon, Gillian Tindall, NORMAN ST JOHN-STEVAS, , E. J. VENN, , C. W. KOENIGSBERGER, , MIKE FABER, , T. V. HARTZ, , E. P. THOMPSON, , NICOLAS WALTER, , CAMPBELL OF CROY, , PHILIP WRIGHT, , STANLEY ARTHUR, PETER TARGETT, , BARNEY TRENCH, , J. F. RUTTER, , FRANK HANSFORD-MILLER, , JULIAN B. BARBOUR, , RUTH ELLACOTT, By Geraldine Norman, Sale Room Correspondent, Arthur Burrell, By John Young, Agriculture Correspondent, David Wade, Irving Wardle, Peter Ackroyd, Peter Davalle, · by Michael Clark, City Editor Anthony Hilton, By Jeremy Warner, By Clive Cookson, Technology Correspondent, By Graham Searjeant, By Peter Wilson-Smith, Banking Correspondent, By Our Financial Staff, By Derek Harris, Commercial Editor, By Our Commercial Editor, Ian McDonald, Margaret Drummond, Peter Gartland, · edited by Sally White, From Ian Murray, Brussels, From John Earle, Rome, By David Hands, Rugby Correspondent, By Gerald Davies, By Pat Butcher, By Keith Macklin, From John Blunsden, Imola, By Peter Ball, From a Special Correspondent, Dallas, By Rex Bellamy, Tennis Correspondent, By Paul Newman, From Mitchell Platts, Florence, By Marcus Williams, By David Hands, By Michael Phillips, Racing Correspondent, From Desmond Stoneham, French Racing Correspondent, Paris, By Michael Seely, By Jenny MacArthur, Edited by Peter Davalle, Michael Hornsby, Edited by Shona Crawford Poole, Robin Young, Ashley Stephenson, , Jane MacQuitty, Paul Griffiths, Hilary Finch, Nicholas Kenyon, Geoff Brown, Christopher Warman, Harry Golombek, Jeremy Flint,
... links doctors and files, Doubts on research into Depo-Provera, Oslo ready to sink foreign sub, Actor fined ...
1983 - Gale Group | TDA
Amy Gillgrass, Ali A. Ashkar, Kenneth L. Rosenthal, Charu Kaushic,
Depo-Provera (Depo) is a long-acting progestational formulation that is a popular form of contraception for women. In animal ...
Tópico(s): Reproductive tract infections research
2003 - American Society for Microbiology | Journal of Virology
Geoff Bish, Elon Salmon, Patrick Jenkin, R.W. Komer,
... Back to nature Drug design On trial again Depo-Provera Modcomp The Royal Bank Of Canada Air France ...
1983 - Gale Group | The Economist
Heather Jarman, Gabor T. Kovacs, Mary Westcott,
... the case histories of 70 users of Depo-Provera (containing depo medroxyprogesterone acetate) were reviewed during April-June 1987 ... obstetric and contraceptive history, and side effects of Depo-Provera use. 47 (67%) were employed; 20 (29%) were ... had used nothing. Age range at start of Depo Provera use was 14-40 years. The reasons given for commencing Depo-Provera included a combination of problems with other methods, ... OCs. 47 (67%) had requested the use of Depo-Provera, of whom 13 (18%) had used it previously. ...
Tópico(s): Maternal and fetal healthcare
1990 - Wiley | Australian and New Zealand Journal of Obstetrics and Gynaecology
David L. Howard, Rebecca Wayman, Julie Strickland,
... the trend was only statistically significant for Depo-Provera. For Depo-Provera, there was a significantly lower proportion of participants ... post-partum/parous adolescents, overall subjective satisfaction with Depo-Provera and the Mirena IUD is similarly high over 12 months of follow-up. With Depo-Provera, however, there appears to be a disconnect between ...
Tópico(s): Maternal and fetal healthcare
2013 - Elsevier BV | Journal of Pediatric and Adolescent Gynecology
Margaret Polaneczky, Michelle LiBlanc,
... pregnancy rates warrant close follow-up after Depo-Provera discontinuation.Depo-Provera continuation rates and reasons for discontinuation among ...
Tópico(s): Pregnancy-related medical research
1998 - Elsevier BV | Journal of Adolescent Health
Zvi Laron, G. Rumney, Rat L, Nazar Ahmed Naji,
ABSTRACT Weekly injections of 17α-hydroxy-6α-methylprogesterone acetate to three patients with gonadal dysgenesis exhibiting high urinary gonadotrophins and one girl with marked enlargement of breasts and high urinary oestrogens, led to suppression of both urinary gonadotrophins and oestrogens in two patients and of oestrogens alone in the third case. There was no significant effect on the urinary 17-ketosteroids or 17-hydroxycorticosteroids.
Tópico(s): Hormonal and reproductive studies
1963 - Oxford University Press | European Journal of Endocrinology
... and Ovrette), depot medroxyprogesterone acetate (DMPA) injections (Depo‐Provera and depo‐subQ provera 104), levonorgestrel intrauterine system (IUS) (Mirena), and etonogestrel ...
Tópico(s): Endometriosis Research and Treatment
2010 - Wiley | Journal of the American Academy of Nurse Practitioners
Barbara A. Cromer, R.D. Smith, Jennifer E. Dwyer, Jamie McArdle Blair, Robert T. Brown,
Levonorgestrel implants (Norplant) and medroxyprogesterone acetate injections (Depo-Provera) represent additional contraception options for adolescents. The purpose of this study was to examine prospectively clinical profiles among adolescents who chose one of ... a contraceptive menu consisting of Norplant (n = 58), Depo-Provera (n = 66), or OCP (n = 75). At baseline ... and 34% white.Significantly more teens who chose Depo-Provera (73%) reported having used some method of birth ... 26%). Adolescents who chose either Norplant (34%) or Depo-Provera (43%) were significantly more likely to have been ...
Tópico(s): Maternal Mental Health During Pregnancy and Postpartum
1994 - American Academy of Pediatrics | PEDIATRICS
... presentation will focus on progestin-only methods, especially Depo-Provera. Epidemiological Data When reviewing epidemiological data, one must ... associated with a possible increase in risk and Depo-Provera with an increase in risk6,7. A meta- ... epithelium is thin or under the influence of Depo-Provera, and is less easily transmitted when the epithelium ... Oophorectomized mice are less susceptible if given estradiol. Depo-Provera allowed transmission whereas Depo-Estradiol blocked it10. In ... progestins led to reversible vaginal thinning (even when Depo-Provera was present at low levels), and that medroxyprogesterone ...
Tópico(s): Herpesvirus Infections and Treatments
2005 - Lippincott Williams & Wilkins | JAIDS Journal of Acquired Immune Deficiency Syndromes
Zeev Harel, Frank M. Biro, Linda M. Kollar, Joseph L. Rauh,
... reasons for discontinuation of the long-acting contraceptives Depo-Provera and Norplant in adolescents, and to assess the ... index (BMI) 24.2 ± 0.61 who discontinued Depo-Provera, and 31 adolescents (gynecologic age 3.4 ± 0. ... 21.8 ± 1.6 months of use) and Depo-Provera (9.2 + 0.9 months of use) were ... noted sooner after discontinuation of Norplant, compared with Depo-Provera. The increase in BMI noted at discontinuation of ... of either method (0.6, P = .01 post-Depo-Provera discontinuation; and 0.9, P = 0.02 post- ... the most popular method (37%) after discontinuation of Depo-Provera, and oral contraceptive (39%) after discontinuation of Norplant. ...
Tópico(s): Adolescent Sexual and Reproductive Health
1996 - Elsevier BV | Journal of Adolescent Health
Zeev Harel, Frank M. Biro, Linda M. Kollar,
... oral contraceptive pills (OCP) on side effects of Depo-Provera during the early months of use in adolescents. ... 1.3) switched directly from an OCP to Depo-Provera. The patients were periodically assessed by their care providers.Early administration of the second injection of Depo-Provera did not alter the bleeding episodes, onset of ... persist beyond the first six months.Early second Depo-Provera injection does not alter the experience of menstrual ... to greater weight gain; OCP use prior to Depo-Provera results in a decrease in the duration of ...
Tópico(s): Pharmacological Effects and Toxicity Studies
1995 - Elsevier BV | Journal of Adolescent Health
Catherine Pamela Edwards, S. Paige Hertweck, Sally E. Perlman, L. Jane Goldsmith, Joseph S. Sanfilippo,
Background Depot medroxyprogesterone acetate (Depo Provera®) is a popular contraceptive method among adolescents. Little is known, however, about the long term effects of Depo Provera® on bone mineral density in adolescent females. This ongoing study prospectively evaluates the effects of Depo Provera® and oral contraceptive pills on bone mineral density, ... to 17 presenting for new start hormonal contraception (Depo Provera®: n = 30, oral contraceptive pills: n = 25) received ... 017 gm/cm2 or 1.8% in the Depo Provera® group (n = 15), and increased by 0.030 ...
Tópico(s): Pharmacological Effects and Toxicity Studies
1998 - Elsevier BV | Journal of Pediatric and Adolescent Gynecology
Research Article| May 01 2018 “Injectable Development”: Depo-Provera and Creation of the Global South Emily Callaci Emily Callaci Search for other works by this author on: This Site Google Radical History ... Permissions Search Site Citation Emily Callaci; “Injectable Development”: Depo-Provera and Creation of the Global South. Radical History ... the Upjohn Corporation approval to produce and sell Depo-Provera—an injectable hormonal contraceptive—in the United States. Simultaneously, development experts promoted Depo-Provera as a form of aid to send abroad, ...
Tópico(s): Historical Studies on Reproduction, Gender, Health, and Societal Changes
2018 - Duke University Press | Radical History Review
... involves regulation of hormone levels through injections of Depo-Provera--a drug which substantially decreases the sex drive ... are involved however. The long-term risks of depo-Provera are unknown and its effect on sexual functions ... convicted of sex offenses can voluntarily consent to depo-Provera treatment and whether those who do consent to ... to such treatment are questioned. This article examines depo-Provera usage potential limitations on state power to impose depo-Provera treatment against an offenders will and the problem ...
Tópico(s): Criminal Justice and Corrections Analysis
1984 - Taylor & Francis | Journal of Legal Medicine
Ian S. Fraser, Graeme Dennerstein,
... of Melbourne, who received injections of 150 mg Depo-Provera every 12 weeks, to determine the experience of ... total of 2298 injections. Most women (80%) used Depo-Provera for contraception. Other common indications for Depo-Provera use were treatment of endometriosis, recurrent candidiasis, and ... it was difficult for her to conceive after Depo-Provera treatment. The most common reason for discontinued use of Depo-Provera was no further need (e.g., sterilization) or ... difficulty with intercourse (8%). These findings confirm that Depo-Provera is a very effective and acceptable contraceptive method. ...
Tópico(s): Housing, Finance, and Neoliberalism
1994 - Wiley | The Medical Journal of Australia
Muluken Fekadie Zerihun, Tabarak Malik, Yohannes Mulu Ferede, Tesfahun Bekele, Yigizie Yeshaw,
Depo-Provera is an injectable contraceptive method containing medroxyprogesterone acetate. It has some adverse effects like changes in ... is aimed at to investigate the effects of Depo-Provera on body weight and blood pressure among Ethiopian ... changes in variables and duration of use of Depo-Provera. P-value ≤ 0.05 were considered as statistically ... mean weight and body mass index (BMI) of Depo-Provera users were increased significantly (p = 0.02 for ... difference in mean arterial blood pressure (MAP) of Depo-Provera users compared to controls or their respective pretreatment ...
Tópico(s): Maternal and fetal healthcare
2019 - BioMed Central | BMC Research Notes
Sydney Segal, Walter R. Anyan, Sanford N. Cohen, John Freeman, Reba M. Hill, Ralph E. Kauffman, Howard C. Mofenson, Albert W. Pruitt, Henry R. Shinefield,
... for use of the injectable progestin, medroxyprogesterone acetate (Depo-Provera), in adolescents. The Committee has reviewed the available ... The Committee has found no conclusive evidence that Depo-Provera is harmful to humans, and it acknowledges that ... undesirable, long-term effects of the use of Depo-Provera that cannot be resolved by the extant data. ... to state that the lack of availability of Depo-Provera as an approved contraceptive agent hinders the provision ... in the United States. The Committee believes that Depo-Provera—or a similar, long-acting contraceptive agent—can ...
Tópico(s): Adolescent Sexual and Reproductive Health
1980 - American Academy of Pediatrics | PEDIATRICS
Ronald H. Gray, Tieng Pardthaisong,
... of women who had used the injectable contraceptive Depo-Provera (The Upjohn Company, Kalamazoo, Michigan), 565 children of ... a panel. The children exposed in utero to Depo-Provera had higher neonatal and infant mortality rates (44. ... odds ratio for death was significantly increased with Depo-Provera exposures due to accidental pregnancy (odds ratio (OR) = ... weight may act as an intermediate determinant of Depo-Provera-associated mortality. Among the accidental pregnancies with Depo-Provera, there was a relation between shorter injection-to- ...
Tópico(s): Reproductive Health and Contraception
1991 - Oxford University Press | American Journal of Epidemiology
Charu Kaushic, Ali A. Ashkar, Lesley A. Reid, Kenneth L. Rosenthal,
ABSTRACT Depo-provera, a long-acting progestational formulation, is widely used to facilitate infection of sexually transmitted diseases in animal ... herpes simplex virus type 2 (HSV-2) after Depo-provera or a saline suspension of progesterone (P-sal). We found that following Depo-provera-treatment, mice had prolonged diestrus that lasted more ... 7 PFU. In addition to alterations in susceptibility, Depo-provera treatment had inhibitory effects on immune responses to ... with HSV-2 protein (gB) and treated with Depo-provera showed significant lowering of local HSV-2-specific ...
Tópico(s): Dermatology and Skin Diseases
2003 - American Society for Microbiology | Journal of Virology
Carley Tasker, Vanessa Pizutelli, Yungtai Lo, Bharat Ramratnam, Natalie Roche, Theresa L. Chang,
Objectives: Depot medroxyprogesterone acetate (Depo-Provera) is the most commonly used injectable hormone contraceptive in Sub-Saharan Africa where HIV incidence is high. We determined the impact of Depo-Provera on cervical immune cells and mediators in healthy ... visit 2), and 3 months (visit 3) after Depo-Provera injection. Cervical cells were collected by cytobrush and ... frequency of cervical central memory CD4 + T cells. Depo-Provera treatment had little effect on expression of immune ... decreased in both vaginal and cervical secretions after Depo-Provera injection. In cervical samples collected by cytobrush, we ...
Tópico(s): Cervical Cancer and HPV Research
2020 - Lippincott Williams & Wilkins | AIDS
Tieng Pardthaisong, Ronald H. Gray,
... the fetus was exposed to the injectable contraceptive Depo-Provera (The Upjohn Company, Kalamazoo, Michigan) (830 accidental pregnancies ... infants conceived before the mother started use of Depo-Provera), 601 accidental pregnancies in women who were using ... records were traced for birth weight. Women using Depo-Provera had more risk factors for adverse pregnancy outcomes ... increased for accidental pregnancies with fetal exposure to Depo-Provera (odds ratio (OR) = 1.5, 95% confidence interval ( ... birth weight among infants exposed in utero to Depo-Provera or oral contraceptives is due in part to ...
Tópico(s): Pregnancy and preeclampsia studies
1991 - Oxford University Press | American Journal of Epidemiology
Meritxell Genescà, Jun Li, Linda Fritts, P Chohan, Kristen Bost, Tracy Rourke, Shelley A. Blozis, Michael B. McChesney, Christopher J. Miller,
... SIVmac239. Three of these animals were treated with Depo‐Provera 30 days prior to the SIV challenge. Results ... levels than the unimmunized control monkeys, but the Depo‐Provera treated, SHIV‐immunized animals did not. Despite the lack of protection, the Depo‐Provera SHIV animals had strong SIV specific T‐cell ... expression prior to SIV challenge were observed in Depo‐Provera SHIV animals. Conclusions Depo‐Provera eliminates live‐attenuated lentivirus vaccine efficacy in male ...
Tópico(s): Reproductive System and Pregnancy
2007 - Wiley | Journal of Medical Primatology
Vera Halpern, Vivian Brache, Douglas Taylor, Anja Lendvay, Leila Cochón, Jeffrey T. Jensen, Laneta J. Dorflinger,
... in the abdomen of 150 or 300 mg Depo-Provera and compare results to two injections of Depo- ... n = 24) or 300 mg (n = 9) of Depo-Provera or two injections of Depo-SubQ Provera 104 ( ... a single injection of 150 or 300 mg Depo-Provera. The 150 mg group had a similar Cmax ... and pharmacokinetics data provide proof of concept that Depo-Provera (150 mg) may be an effective contraceptive method ...
Tópico(s): Maternal and fetal healthcare
2021 - Elsevier BV | Fertility and Sterility